• Overview
  • Eligibility
  • More info
  • Locations

A Multi-center, Randomized, Double Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled (NCT03026933)

To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.
  • Drug: KI1107 4 Capsules, QD
    KI1107 4 Capsules
    • Drug: Rosuvastatin Calcium 20 MG, QD
      Rosuvastatin Calcium 20mg, QD
      Ages eligible for Study
      19 Years to 80 Years
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      Study design:

      Randomly assigned to two groups(KI1107 or Rosuvastatin monotherpy) after 4 weeks run-in period and prescribed KI1107 or Rosuvastatin for 8 weeks.
      Status:
      completed
      Type:
      Interventional
      Phase:
      Start:
      30 April, 2014
      Updated:
      18 January, 2017
      Participants:
      215
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!